Mechlorethamine

Summary

Mechlorethamine (CHEMBL427) is an approved small molecule (ATC L01AA05); indicated across 6 conditions including mycosis fungoides and neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01AA05
• Indications: 6 conditions
• Clinical trials: 6
• Chemistry: 156.05 Da · C5H11Cl2N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL427
Name	Mechlorethamine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4033
ChEBI	CHEBI:28925
ATC	L01AA05
Molecular formula	C5H11Cl2N
Molecular weight	156.05
InChIKey	HAWPXGHAZFHHAD-UHFFFAOYSA-N

SMILES: CN(CCCl)CCCl

IUPAC name: 2-chloro-N-(2-chloroethyl)-N-methylethanamine

Also known as: Chlorethazine, Chlormethine, Clormetina, Ledaga, Mechlorethamine, Nitrogen mustard (hn 2), NSC-10107, NSC-128663, NSC-757087, Mustine, Embichin, SID26747396

Parent form; salt/anhydrous children: CHEMBL1201001

Patent coverage: 36,261 distinct patent families (140,362 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Microtubule-associated protein tau, Nuclear receptor ROR-gamma.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
mycosis fungoides	4	MONDO:0009691	EFO:1001051
neoplasm	4	MONDO:0005070	EFO:0000616
lymphoma	3	MONDO:0005062	EFO:0000574
Hodgkins lymphoma	2	MONDO:0004952	EFO:0000183
lichen planus	2	MONDO:0006572	EFO:0009856
primary cutaneous T-cell non-Hodgkin lymphoma	2	MONDO:0000607	EFO:0002913

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE2	3
Not specified	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00003389	PHASE3	COMPLETED	Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin’s Lymphoma
NCT00352027	PHASE2	COMPLETED	Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
NCT03288818	PHASE2	WITHDRAWN	Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides
NCT03417141	PHASE2	COMPLETED	Valchlor in the Treatment of Lichen Planopilaris
NCT05106192	Not specified	WITHDRAWN	Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.
NCT05303480	Not specified	COMPLETED	Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).